Form 8-K/A

8-K/A — Aspire Biopharma Holdings, Inc.

Accession: 0001493152-26-017145

Filed: 2026-04-17

Period: 2026-04-15

CIK: 0001847345

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item: Financial Statements and Exhibits

Documents

8-K/A — form8-ka.htm (Primary)

EX-3.1 (ex3-1.htm)

GRAPHIC (ex3-1_001.jpg)

GRAPHIC (ex3-1_002.jpg)

GRAPHIC (ex3-1_003.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K/A

8-K/A (Primary)

Filename: form8-ka.htm · Sequence: 1

true

--12-31

0001847345

2026-04-15

0001847345

ASBP:CommonStockParValue0.0001PerShareMember

2026-04-15

0001847345

ASBP:WarrantsEachExercisableForOneShareOfCommonStockMember

2026-04-15

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K/A

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): April 15, 2026

Aspire

Biopharma Holdings, Inc.

(Exact

Name of Registrant as Specified in Its Charter)

Delaware

001-41293

33-3467744

(State

or other jurisdiction

incorporation)

(Commission

File

No.)

(I.R.S.

Employer

Identification

No.)

23150

Fashion Drive, Suite 232

Estero,

Florida 33928

(Address

of Principal Executive Offices)

(415)

592-7399

(Registrant’s

Telephone Number)

194

Candelaro Drive, #233

Humacao,

PR 00791

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

stock, par value $0.0001 per share

ASBP

The

Nasdaq Stock Market LLC

Warrants,

each exercisable for one share of common stock

ASBPW

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

EXPLANATORY

NOTE

This

Amendment No. 1 to the Current Report on Form 8-K amends and restates the Current Report on Form 8-K, filed on April 16, 2026, in

order to correct certain disclosure inaccuracies.

Item

1.01. Entry into a Material Definitive Agreement.

Securities

Purchase Agreement

previously reported, in the Company’s Current Report on Form 8-K filed on February 6, 2026 (the “February 8-K”),

Aspire Biopharma Holdings, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities

Purchase Agreement”) with certain accredited investors (the “Investors”), providing for a private placement

(the “Offering”), of up to 25,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”),

convertible into shares of the Company’s common stock (the “Common Stock”). The terms of the Securities Purchase

Agreement, the Preferred Stock, and the related Certificate of Designations, Preferences and Rights of the Series A Convertible Preferred

Stock, as amended (the “Certificate of Designation”) are described in the February 8-K and are incorporated herein

by reference. This Current Report on Form 8-K reports the closing of the second tranche of the Offering.

The

Securities Purchase Agreement and Registration Rights Agreement were previously filed as Exhibits 10.1 and 10.2, respectively, to the

February 8-K and are incorporated herein by reference. The summary of the terms of the Certificate of Designation and the Securities

Purchase Agreement and Registration Rights Agreement in the February 8-K are subject to, and qualified in their entirety by, the full

text of such documents, which are incorporated herein by reference from the February 8-K.

statement in this report or the attached exhibits is an offer to sell or a solicitation of an offer to purchase the Company’s securities,

and no offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

The

Offering

previously disclosed, on February 6, 2026, the Company closed the first tranche of the Offering for an aggregate of 13,750 Shares, resulting

in gross proceeds of $11,000,000 including the conversion of $943,801 in existing debt into Shares on the same terms. On April 15, 2026,

the Company and the investors closed on the second tranche of the Offering for an aggregate of 12,500 Shares, resulting in gross proceeds

of approximately $10,000,000. In both tranches, gross proceeds are before deducting fees to be paid to the placement agents and financial

advisors of the Company and other estimated offering expenses payable by the Company. Proceeds from the $21,000,000 Offering net

of transaction fees and expenses will be available to fund the cash component of the proposed Dura Driver Control Systems acquisition

and for general corporate purposes.

RBW

Capital Partners acting through Dawson James Securities Inc., served as placement agent on the transaction.

Item

5.03. Amendments to Articles of Incorporation or Bylaws: Change in Fiscal Year.

April 13, 2026, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Certificate

of Designation of Series A Convertible Preferred Stock (the “Certificate of Amendment”).

The

Certificate of Amendment amends the Company’s previously filed Certificate of Designation of Series A Convertible Preferred Stock,

which was originally filed on February 2, 2026.

Pursuant

to the Certificate of Amendment, the Company amended certain provisions of the Certificate of Designation, including clarifying and restating

provisions relating to the designation and number of shares of Series A Convertible Preferred Stock. As amended, the Company has designated

30,000 shares of Series A Convertible Preferred Stock, each with a par value of $0.0001 and a stated value of $1,000 per share.

Except

as expressly modified by the Certificate of Amendment, the Certificate of Designation remains in full force and effect.

The

foregoing description of the Certificate of Amendment is qualified in its entirety by reference to the full text of the Certificate of

Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Forward-Looking

Statements

This

Current Report on Form 8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of

1995, including without limitation statements regarding the Company’s intended use of the net proceeds from the Offering. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important

factors that could cause actual results to differ materially include: risks associated with market conditions; risks associated with

the Company’s cash needs; and risks and uncertainties associated with the Company’s business and finances in general; and

other risks and uncertainties set forth from time to time in the Company’s filings with the Commission. Any forward-looking statements

contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company expressly disclaims any obligation to

update any forward-looking statements, whether because of new information, future events or otherwise.

Item

9.01 Financial Statements and Exhibits.

Exhibit

Number

Description

3.1

Certificate of Amendment to the Certificate of Designation of Series A Convertible Preferred Stock, filed with the Secretary of State of the State of Delaware on April 13, 2026

10.1

Form of Securities Purchase Agreement, dated February 6, 2026 by and among Aspire Biopharma Holdings, Inc. and the purchasers named therein (incorporated by reference to the current report on Form 8-K, filed on by the Company on February 12, 2026)

10.2

Form of Registration Rights Agreement, dated February 6, 2026 by and among Aspire Biopharma Holdings, Inc. and the holders named therein (incorporated by reference to the current report on Form 8-K, filed on by the Company on February 12, 2026)

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

ASPIRE

BIOPHARMA HOLDINGS, INC.

By:

/s/

Ernest Scheidemann

Ernest

Scheidemann

Chief

Financial Officer

Date:

April 17, 2026

EX-3.1

Filename: ex3-1.htm · Sequence: 2

Exhibit 3.1

GRAPHIC

Filename: ex3-1_001.jpg · Sequence: 3

Binary file (309155 bytes)

Download ex3-1_001.jpg

GRAPHIC

Filename: ex3-1_002.jpg · Sequence: 4

Binary file (564237 bytes)

Download ex3-1_002.jpg

GRAPHIC

Filename: ex3-1_003.jpg · Sequence: 5

Binary file (191814 bytes)

Download ex3-1_003.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 11

v3.26.1

Cover

Apr. 15, 2026

Document Type

8-K/A

Amendment Flag

true

Amendment Description

This

Amendment No. 1 to the Current Report on Form 8-K amends and restates the Current Report on Form 8-K, filed on April 16, 2026, in

order to correct certain disclosure inaccuracies.

Document Period End Date

Apr. 15, 2026

Current Fiscal Year End Date

--12-31

Entity File Number

001-41293

Entity Registrant Name

Aspire

Biopharma Holdings, Inc.

Entity Central Index Key

0001847345

Entity Tax Identification Number

33-3467744

Entity Incorporation, State or Country Code

Entity Address, Address Line One

23150

Fashion Drive

Entity Address, Address Line Two

Suite 232

Entity Address, City or Town

Estero

Entity Address, State or Province

Entity Address, Postal Zip Code

33928

City Area Code

(415)

Local Phone Number

592-7399

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common stock, par value $0.0001 per share

Title of 12(b) Security

Common

stock, par value $0.0001 per share

Trading Symbol

ASBP

Security Exchange Name

NASDAQ

Warrants, each exercisable for one share of common stock

Title of 12(b) Security

Warrants,

each exercisable for one share of common stock

Trading Symbol

ASBPW

Security Exchange Name

NASDAQ

- Definition

Description of changes contained within amended document.

+ References

No definition available.

+ Details

Name:

dei_AmendmentDescription

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name:

dei_CurrentFiscalYearEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:gMonthDayItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=ASBP_CommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=ASBP_WarrantsEachExercisableForOneShareOfCommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: